** Shares of India's Sun Pharma SUN.NS climb 3% to 1,656.25 rupees
** SUN top pct gainer on pharma index .NIPHARM and second-biggest gainer on Nifty 50 .NSEI
** India's top drugmaker by revenue to acquire U.S.-based Checkpoint Therapeutics CKPT.O for $355 million
$1 BILLION OPPORTUNITY
** JP Morgan ("overweight", PT: 2,210 rupees) says Checkpoint acquisition "checks the boxes" as it gives SUN access to a US FDA approved skin cancer drug Unloxcyt, which has potential to become a $1 billion opportunity in US
** Adds, acquisition will bolster SUN's specialty offerings in skin cancer space, which has been one of its key focus areas
** BofA Securities ("neutral", PT: 1,940 rupees) says Unloxcyt has an advantage over rivals' drugs due to lower price, but says it awaits clarity on SUN's commercial strategy
** Motilal Oswal ("buy", PT: 1,895 rupees) says SUN is "on a spree to expand specialty portfolio" and Checkpoint's five cancer treatment assets to complement SUN's existing portfolio
(Reporting by Kashish Tandon in Bengaluru)
((Kashish.tandon@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。